Sorrento Therapeutics, Inc.
SRNE
SRNE was delisted on the 22nd of February, 2023.
4 hedge funds and large institutions have $380 invested in Sorrento Therapeutics, Inc. in 2026 Q1 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and 2 closing their positions.
363% more capital invested
Capital invested by funds: $82 → $380 (+$298)
20% less funds holding
Funds holding: 5 → 4 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VWA
VSM Wealth Advisory
Hunt Valley,
Maryland
|
+$363 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KWA
Kingswood Wealth Advisors
San Diego,
California
|
-$67 |
SRNE Hedge Fund Activity: Q1 2026 in Review
4 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Sorrento Therapeutics, Inc. (SRNE) for Q1 2026, worth a combined $380 — up 363% from $82 a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of SRNE and 1 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest buyer was VSM Wealth Advisory, opening a new position worth an estimated $363. The largest seller was Kingswood Wealth Advisors, exiting entirely with an estimated $67 sold.
- 4 institutional investors held Sorrento Therapeutics, Inc. (SRNE) as of Q1 2026, down from 5 in Q4 2025.
- Funds reported $380 of Sorrento Therapeutics, Inc. stock for Q1 2026, up 363% quarter-over-quarter.
- 1 fund opened new Sorrento Therapeutics, Inc. positions in Q1 2026 and 2 closed out, a net change of -1 holder.
- The largest Sorrento Therapeutics, Inc. buyer in Q1 2026 was VSM Wealth Advisory, an estimated $363 added.
- The largest Sorrento Therapeutics, Inc. seller in Q1 2026 was Kingswood Wealth Advisors, an estimated $67 sold.
Based on aggregated 13F filings for Q1 2026.